Microsoft word - 20th european congress of clinical microbiology.doc
20th European Congress of Clinical Microbiology and Infectious
Home - 11.04.2010 - Emerging influenza virus: H1N1v and H5N1
Emerging influenza virus: H1N1v and H5N1
Sunday, April 11, 2010, 13:30 - 14:30 Antibodies to interferon-gamma in ultra-low doses: a new option for
S. Tarasov*, V. Zarubaev, J. Tafani, J. Dugina, S. Sergeeva, O. Epstein (Moscow, St. Petersburg, RU;
Maisons Alfort, FR)
Objectives: To assess antiviral activity of antibodies to interferon gamma in ultralow
doses (ULDabIFNg) against influenza A/H1N1 viruses.
Methods: Antiviral activity of ULDabIFNg (Anaferon for children®) was studied in
experimental models of lethal infection of mice infected by different influenza A/H1N1
virus strains. Studies were conducted in Influenza Research Institute (Russia) and in
APcis (France) in 2009. In Influenza Research Institute 100 female outbred mice (16-18
g., 20 mice/group) were infected intranasally with 10LD50 of influenza virus
A/California/07/2009swl. In APcis 60 female Balb/c mice (10-12 g., 20 mice/group) were
infected intranasally with 3LD50 of influenza virus A/NewCaledonia/20/99. In both
studies ULDabIFNg given as water solution were administered according to
prophylactic/treatment regimen (5 days before and 12 days after inoculation) via oral
gavage (0.2 ml/mice 2 times/day). Besides ULDabIFNg were given instead of drinking
water. Control mice were given distilled water according to the same schedule. In
negative control group mice were neither infected nor treated. In Influenza Research
Institute efficacy of combination of ULDabIFNg with oseltamivir against monotherapy
with oseltamivir was also studied. Oseltamivir was administered according to
prophylactic/treatment regimen (25 hours and 1 hour before and 3 days after
inoculation) via oral gavage (0.2 ml/mice 2 times/day at dose 20 mg/kg/day) or (Apcis)
from 1 hour to 5 days after inoculation (10 mg/kg/day). Combination of ULDabIFNg with
oseltamivir was prepared by dissolving oseltamivir in water solution of ULDabIFNg.
Mortality rate and body weight change were evaluated.
Results: In Influenza Research Institute ULDabIFNg significantly reduced mortality. In
control group survival was 12.5%, in oseltamivir group – 10%, in ULDabIFNg group –
50%, in oseltamivir+ULDabIFNg group – 35%. In the second study (APcis) in the control
group inoculation caused deaths 60% of mice on day 7, treatment with ULDabIFNg
resulted in a later disease onset (on day 5 in ULDabIFNg group mortality was 15% vs
40% in control group). In both studies mean body weight of alive mice was constantly a
positive function of time in group treated with ULDabIFNg.
Conclusion: Antiviral activity of ULDabIFNg against two strains of influenza A/H1N1
viruses including the pandemic one is comparable to oseltamivir. Combination of
ULDabIFNg with oseltamivir increases the efficacy of monotherapy with oseltamivir.
Only for the use of a Registered Medical Practitioner or a Hospital or a Laboratory. Metformin Hydrochloride and Voglibose Tablets METADOZE V- 0.2/0.3 METADOZE V - 0.2 Distribution: COMPOSITION After ingestion of voglibose (and other glucosidase inhibitors), the majority of active Each uncoated bi-layered tablet contains unchanged drug remains in the lumen of the gastrointestinal t
Please check the boxes that you feel passionate about and then create your own plan using the information here. Full Name: __________________________________ Partner’s Name: ____________________________ Today’s Date: ________________________________ Due Date/Induction Date: ____________________ Careprovider’s Name: _________________________ Hospital Name: _____________________________